Aptose Biosciences GAAP EPS of -$0.73 beats by $0.09
Aptose Biosciences Launches AML Triplet Therapy Study
Aptose Biosciences Unveils Q1 Results and Clinical Update
What Makes Aptose Biosciences (APTO) a New Buy Stock
Piper Sandler Keeps Their Buy Rating on Aptose Biosciences (APTO)
Piper Sandler Keeps Their Buy Rating on Aptose Biosciences (APTO)
Aptose Biosciences’ Strategic Shift to Front-Line AML Therapy Garners Buy Rating
Wall Street Analysts Are Bullish on Top Healthcare Picks
Aptose Biosciences Expands AML Treatment Trials
Aptose Biosciences Unveils Upcoming Financials
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.